fluconazole has been researched along with Foot Dermatoses in 34 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
Foot Dermatoses: Skin diseases of the foot, general or unspecified.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole." | 9.12 | [Fluconazole and treatment of onychomycosis. About 86 cases]. ( Ben Osman Dhahril, A; Bouassida, S; Denguezli, M; Doss, N; El Euch, D; Ezzine, N; Kourda, M; Mokhtar, I; Nouira, R; Ridha Kamoun, M; Turki, H, 2006) |
| "To determine the cost effectiveness of terbinafine (Lamisil) tablets compared with fluconazole (Diflucan) capsules in the treatment of patients with toenail onychomycosis." | 9.10 | Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. ( Pekurinen, M; Salo, H, 2002) |
| "The results of this study support the use of fluconazole in the treatment of distal subungual onychomycosis of the toenail caused by dermatophytes." | 9.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "Results of this study support the efficacy and safety of fluconazole in the treatment of distal subungual onychomycosis of the toenail." | 9.08 | Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. ( Asarch, RG; Babel, D; Bergfeld, WF; Cook, J; Drake, L; Eaglstein, WH; Falanga, V; Falo, L; Hanifin, JM; Jarratt, MT; Kalivas, J; Katz, HI; Lebwohl, MG; Leyden, JJ; Ling, MR; Martin, AG; Monroe, EW; Pariser, DM; Pariser, R; Stewart, DM; Swinyer, LJ; Tharp, M; Thiers, BH; Weinstein, GD; Young, MR, 1998) |
| "Preliminary clinical data suggest that fluconazole is effective in the treatment of patients with onychomycosis." | 9.08 | Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Hilbert, J; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 8.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| "The aims of this study were to report the high prevalence of onychomycosis by Fusarium spp." | 7.74 | Fusarium spp. as agents of onychomycosis in immunocompetent hosts. ( Guilhermetti, E; Shinobu, CS; Svidzinski, TI; Takahachi, G, 2007) |
| "Intermittent fluconazole, taken once weekly or on alternate days, is a well-tolerated and efficacious method to treat onychomycosis." | 7.69 | Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. ( Assaf, RR; Elewski, BE, 1996) |
| "We report three cases of sporotrichosis successfully treated with oral fluconazole." | 7.68 | Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. ( Belda Júnior, W; Castro, LG; Cucé, LC; Sampaio, SA; Stevens, DA, 1993) |
| "Systemic treatment of onychomycosis is based these last years on the new drug utilization aiming to decrease the length of the treatment and secondary effects particularly with fluconazole." | 5.12 | [Fluconazole and treatment of onychomycosis. About 86 cases]. ( Ben Osman Dhahril, A; Bouassida, S; Denguezli, M; Doss, N; El Euch, D; Ezzine, N; Kourda, M; Mokhtar, I; Nouira, R; Ridha Kamoun, M; Turki, H, 2006) |
| "To determine the cost effectiveness of terbinafine (Lamisil) tablets compared with fluconazole (Diflucan) capsules in the treatment of patients with toenail onychomycosis." | 5.10 | Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis. ( Pekurinen, M; Salo, H, 2002) |
| "The results of this study support the use of fluconazole in the treatment of distal subungual onychomycosis of the toenail caused by dermatophytes." | 5.08 | Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "Results of this study support the efficacy and safety of fluconazole in the treatment of distal subungual onychomycosis of the toenail." | 5.08 | Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail. ( Asarch, RG; Babel, D; Bergfeld, WF; Cook, J; Drake, L; Eaglstein, WH; Falanga, V; Falo, L; Hanifin, JM; Jarratt, MT; Kalivas, J; Katz, HI; Lebwohl, MG; Leyden, JJ; Ling, MR; Martin, AG; Monroe, EW; Pariser, DM; Pariser, R; Stewart, DM; Swinyer, LJ; Tharp, M; Thiers, BH; Weinstein, GD; Young, MR, 1998) |
| "Preliminary clinical data suggest that fluconazole is effective in the treatment of patients with onychomycosis." | 5.08 | Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail. ( Aly, R; Breneman, D; Bucko, AD; Elewski, BE; Feingold, DS; Greer, DL; Hilbert, J; Konnikov, N; Levine, N; Lowe, NJ; Morman, MR; Odom, RB; Pinnell, S; Rich, P; Savin, RC; Scher, RK; Shupack, JL; Smith, EB; Tschen, EH, 1998) |
| "To review the use of the new oral antifungal agents, itraconazole, terbinafine and fluconazole for the treatment of onychomycosis of the toenails." | 4.80 | The new oral antifungal agents for onychomycosis of the toenails. ( Gupta, AK; Shear, NH, 1999) |
| "Ciclopirox nail lacquer solution 8% is a recent addition to the armamentarium of therapies available to the physician and patient for the treatment of onychomycosis." | 4.80 | Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States. ( Gupta, AK, 2000) |
| " Griseofulvin, the only drug approved by the Food and Drug Administration for the systemic treatment of onychomycosis, has a cure rate that seldom exceeds 40%." | 4.79 | The systemic treatment of onychomycosis. ( Wenig, JA, 1995) |
| "In 1996, oral terbinafine joined itraconazole and fluconazole on the short list of systemic medications that could be used to treat onychomycosis (although fluconazole was not approved for this indication by the US Food and Drug Administration [FDA], it was commonly used for this purpose)." | 3.83 | Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action. ( Rosen, T; Stein Gold, LF, 2016) |
| "The aims of this study were to report the high prevalence of onychomycosis by Fusarium spp." | 3.74 | Fusarium spp. as agents of onychomycosis in immunocompetent hosts. ( Guilhermetti, E; Shinobu, CS; Svidzinski, TI; Takahachi, G, 2007) |
| "Intermittent fluconazole, taken once weekly or on alternate days, is a well-tolerated and efficacious method to treat onychomycosis." | 3.69 | Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study. ( Assaf, RR; Elewski, BE, 1996) |
| "We report three cases of sporotrichosis successfully treated with oral fluconazole." | 3.68 | Successful treatment of sporotrichosis with oral fluconazole: a report of three cases. ( Belda Júnior, W; Castro, LG; Cucé, LC; Sampaio, SA; Stevens, DA, 1993) |
| "Onychomycosis is a common fungal disease infecting up to 20% of the population over age 40." | 2.69 | Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. ( Bradley, MC; Elewski, BE; Ghannoum, MA; Isham, N; Leidich, S, 1999) |
| "Onychomycosis is a frequent nail disease caused by dermatophytes, yeasts, and nondermatophyte molds." | 2.46 | Onychomycosis. ( Vera-Cabrera, L; Welsh, E; Welsh, O, 2010) |
| "In the treatment of onychomycosis, compliance and drug interactions are important considerations, as diabetic patients frequently take concomitant medications." | 2.45 | Toenail onychomycosis in diabetic patients: issues and management. ( Budihardja, D; Freund, V; Mayser, P, 2009) |
| "Onychomycosis is a public health concern because of its high world wide prevalence, and its potential for spread of fungal elements to others." | 2.41 | [How to improve efficacy of onychomycosis treatment?]. ( Nowicki, R, 2001) |
| " In addition, the short treatment times (< 3 months) and intermittent dosing schedules are likely to enhance compliance and reduce the costs of therapy." | 2.40 | Onychomycosis: pathogenesis, diagnosis, and management. ( Elewski, BE, 1998) |
| "The management of onychomycosis has changed considerably in the past few years." | 2.38 | Onychomycosis. Agents of choice. ( Hay, RJ, 1993) |
| "Fluconazole (Fungolon) has only been recently used in the treatment of nail fungal infections." | 1.32 | Fluconazole (Fungolon) in the treatment of onychomycoses. ( Zisova, LG, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 15 (44.12) | 18.2507 |
| 2000's | 12 (35.29) | 29.6817 |
| 2010's | 7 (20.59) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liang, SE | 1 |
| Cohen, DE | 1 |
| Rieder, EA | 1 |
| Fida, M | 1 |
| Saraceno, R | 1 |
| Gjylametaj, N | 1 |
| Dervishi, O | 1 |
| Barbullushi, A | 1 |
| Kellici, S | 1 |
| Vasili, E | 1 |
| Hryncewicz-Gwóźdź, A | 1 |
| Plomer-Niezgoda, E | 1 |
| Kalinowska, K | 1 |
| Czarnecka, A | 1 |
| Maj, J | 1 |
| Jagielski, T | 1 |
| Rosen, T | 1 |
| Stein Gold, LF | 1 |
| Mayser, P | 1 |
| Freund, V | 1 |
| Budihardja, D | 1 |
| Baudraz-Rosselet, F | 1 |
| Ruffieux, C | 1 |
| Lurati, M | 1 |
| Bontems, O | 1 |
| Monod, M | 1 |
| Fauconneau, A | 1 |
| Lalanne, N | 1 |
| Couprie, B | 1 |
| Pujol, S | 1 |
| Taieb, A | 1 |
| Jouary, T | 1 |
| Welsh, O | 1 |
| Vera-Cabrera, L | 1 |
| Welsh, E | 1 |
| Rao, R | 1 |
| Shenoi, SD | 1 |
| Zisova, LG | 1 |
| Negroni, R | 1 |
| Tuculet, MA | 1 |
| Hiruma, M | 1 |
| Nowicki, R | 1 |
| El Euch, D | 1 |
| Bouassida, S | 1 |
| Kourda, M | 1 |
| Ezzine, N | 1 |
| Denguezli, M | 1 |
| Mokhtar, I | 1 |
| Doss, N | 1 |
| Turki, H | 1 |
| Ridha Kamoun, M | 1 |
| Nouira, R | 1 |
| Ben Osman Dhahril, A | 1 |
| Guilhermetti, E | 1 |
| Takahachi, G | 1 |
| Shinobu, CS | 1 |
| Svidzinski, TI | 1 |
| Schmid-Wendtner, MH | 1 |
| Korting, HC | 1 |
| Wenig, JA | 1 |
| Hay, RJ | 1 |
| Castro, LG | 1 |
| Belda Júnior, W | 1 |
| Cucé, LC | 1 |
| Sampaio, SA | 1 |
| Stevens, DA | 1 |
| Assaf, RR | 1 |
| Elewski, BE | 6 |
| Montero-Gei, F | 1 |
| Robles-Soto, ME | 1 |
| Schlager, H | 1 |
| Joseph, WS | 1 |
| Scher, RK | 2 |
| Breneman, D | 2 |
| Rich, P | 2 |
| Savin, RC | 2 |
| Feingold, DS | 2 |
| Konnikov, N | 2 |
| Shupack, JL | 2 |
| Pinnell, S | 2 |
| Levine, N | 2 |
| Lowe, NJ | 2 |
| Aly, R | 2 |
| Odom, RB | 2 |
| Greer, DL | 2 |
| Morman, MR | 2 |
| Bucko, AD | 2 |
| Tschen, EH | 2 |
| Smith, EB | 2 |
| Ling, MR | 1 |
| Swinyer, LJ | 1 |
| Jarratt, MT | 1 |
| Falo, L | 1 |
| Monroe, EW | 1 |
| Tharp, M | 1 |
| Kalivas, J | 1 |
| Weinstein, GD | 1 |
| Asarch, RG | 1 |
| Drake, L | 1 |
| Martin, AG | 1 |
| Leyden, JJ | 1 |
| Cook, J | 1 |
| Pariser, DM | 1 |
| Pariser, R | 1 |
| Thiers, BH | 1 |
| Lebwohl, MG | 1 |
| Babel, D | 1 |
| Stewart, DM | 1 |
| Eaglstein, WH | 1 |
| Falanga, V | 1 |
| Katz, HI | 1 |
| Bergfeld, WF | 1 |
| Hanifin, JM | 1 |
| Young, MR | 1 |
| Hilbert, J | 1 |
| Gupta, AK | 4 |
| Lambert, J | 1 |
| Shear, NH | 1 |
| Bradley, MC | 1 |
| Leidich, S | 1 |
| Isham, N | 1 |
| Ghannoum, MA | 1 |
| Gregurek-Novak, T | 1 |
| Salo, H | 1 |
| Pekurinen, M | 1 |
| Baran, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Effectiveness of Topical Amphotericin B in 30% Dimethylsulphoxide and 30% Dimethylsulphoxide in Treating of Non-dermatophytes Onychomycosis: Randomized Double Blind Controlled Trial Pilot Study[NCT03814343] | Phase 4 | 19 participants (Actual) | Interventional | 2019-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 reviews available for fluconazole and Foot Dermatoses
| Article | Year |
|---|---|
Proximal Subungual Onychomycosis in the Immunocompetent: A Case Report and Review of the Literature.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Foot Dermatoses; Humans; Immunocompetence; Mal | 2018 |
Toenail onychomycosis in diabetic patients: issues and management.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Ciclopirox; Comorbidity; Diabetes | 2009 |
Onychomycosis.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Ciclopirox; Drug Administration | 2010 |
Acrokeratosis paraneoplastica (Bazex syndrome): an atypical presentation.
Topics: Adenocarcinoma; Antifungal Agents; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Hyperpigme | 2004 |
[Onychomycosis: recent progress in the epidemiology, diagnosis and treatment].
Topics: Administration, Topical; Antifungal Agents; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; I | 2006 |
[How to improve efficacy of onychomycosis treatment?].
Topics: Administration, Topical; Aged; Aged, 80 and over; Antifungal Agents; Dermatomycoses; Drug Therapy, C | 2001 |
Effective treatment for dermatophytoses of the foot: effect on restoration of depressed cell-mediated immunity.
Topics: Animals; Antifungal Agents; Fluconazole; Foot Dermatoses; Humans; Immunity, Cellular; Itraconazole; | 2007 |
The systemic treatment of onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itracon | 1995 |
Onychomycosis. Agents of choice.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Candidiasis, Cutaneous; Fluconaz | 1993 |
Oral treatment options for onychomycosis.
Topics: Administration, Oral; Antifungal Agents; Drug Interactions; Fluconazole; Foot Dermatoses; Humans; It | 1997 |
Once-weekly fluconazole in the treatment of onychomycosis: introduction.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Fluconazole; Foot Dermatoses; Han | 1998 |
Onychomycosis: pathogenesis, diagnosis, and management.
Topics: Adult; Antifungal Agents; Child; Diagnosis, Differential; Female; Fluconazole; Foot Dermatoses; Hand | 1998 |
Pharmacoeconomic analysis of the new oral antifungal agents used to treat toenail onychomycosis in the USA.
Topics: Administration, Oral; Antifungal Agents; Cost-Benefit Analysis; Drug Costs; Economics, Pharmaceutica | 1999 |
The new oral antifungal agents for onychomycosis of the toenails.
Topics: Administration, Oral; Antifungal Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; | 1999 |
Pharmacoeconomic analysis of ciclopirox nail lacquer solution 8% and the new oral antifungal agents used to treat dermatophyte toe onychomycosis in the United States.
Topics: Administration, Oral; Administration, Topical; Antifungal Agents; Arthrodermataceae; Ciclopirox; Cos | 2000 |
9 trials available for fluconazole and Foot Dermatoses
| Article | Year |
|---|---|
Efficacy of fluconazole at a 400 mg weekly dose for the treatment of onychomycosis.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Drug Administration Schedule; Female; Fluconazole; Foot | 2015 |
[Fluconazole and treatment of onychomycosis. About 86 cases].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Female; Fluconazole; Follow-Up Studies; Foot Dermatoses; | 2006 |
Fluconazole in the treatment of severe onychomycosis.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antifungal Agents; Arthrodermataceae; Female; Fluconazole; | 1996 |
Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dose-Response Relationship, Drug; Dou | 1998 |
Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail.
Topics: Adolescent; Adult; Aged; Antifungal Agents; Arthrodermataceae; Dose-Response Relationship, Drug; Dou | 1998 |
Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail.
Topics: Antifungal Agents; Double-Blind Method; Drug Administration Schedule; Female; Fluconazole; Foot Derm | 1998 |
Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Foot Dermatoses; Griseofulvin; Humans; Itraconazole; | 1999 |
Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Topics: Adult; Antifungal Agents; Female; Fluconazole; Follow-Up Studies; Foot Dermatoses; Gastrointestinal | 2001 |
Cost effectiveness of oral terbinafine (Lamisil) compared with oral fluconazole (Diflucan) in the treatment of patients with toenail onychomycosis.
Topics: Administration, Oral; Adult; Aged; Antifungal Agents; Cost-Benefit Analysis; Double-Blind Method; Fe | 2002 |
10 other studies available for fluconazole and Foot Dermatoses
| Article | Year |
|---|---|
Eumycetoma pedis in an Albanian farmer.
Topics: Antifungal Agents; Diagnosis, Differential; Farmers; Fluconazole; Foot Dermatoses; Humans; Itraconaz | 2018 |
Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
Topics: Administration, Cutaneous; Administration, Oral; Antifungal Agents; Boron Compounds; Bridged Bicyclo | 2016 |
Onychomycosis insensitive to systemic terbinafine and azole treatments reveals non-dermatophyte moulds as infectious agents.
Topics: Acremonium; Adult; Antifungal Agents; Aspergillus; Female; Fluconazole; Foot Dermatoses; Fusarium; H | 2010 |
[Pigmented nodular lesion of the foot].
Topics: Alternaria; Antifungal Agents; Biopsy; Dermatomycoses; Fluconazole; Foot Dermatoses; Humans; Male; M | 2010 |
Fluconazole (Fungolon) in the treatment of onychomycoses.
Topics: Adult; Aged; Antifungal Agents; Female; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Male; | 2004 |
[Clinical cases in medical mycology. Case No. 16].
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antifungal Agents; Blood Sedimen | 2005 |
Fusarium spp. as agents of onychomycosis in immunocompetent hosts.
Topics: Adult; Aged; Amphotericin B; Antifungal Agents; Brazil; Female; Fluconazole; Foot Dermatoses; Fusari | 2007 |
Successful treatment of sporotrichosis with oral fluconazole: a report of three cases.
Topics: Administration, Oral; Adult; Fluconazole; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Age | 1993 |
Intermittent fluconazole dosing in patients with onychomycosis: results of a pilot study.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antifun | 1996 |
[New treatments of onychomycoses].
Topics: Administration, Topical; Antifungal Agents; Candidiasis; Ciclopirox; Fluconazole; Foot Dermatoses; H | 1992 |